Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a

Trial Profile

Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Shigella flexneri 2A vaccine (Primary)
  • Indications Bacillary dysentery
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors LimmaTech Biologics
  • Most Recent Events

    • 23 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.
    • 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top